What is RareCyte?
RareCyte is an innovative life science enterprise specializing in the development of sophisticated technologies for the analysis of rare single cells. By providing researchers and clinicians with the tools to isolate and characterize cells that are otherwise difficult to detect, the company plays a pivotal role in oncology research, prenatal diagnostics, and infectious disease monitoring. Its market position is defined by a commitment to high-precision instrumentation and software that enhances the accuracy of liquid biopsy and cellular analysis workflows. As the demand for non-invasive diagnostic tools grows, RareCyte remains at the forefront of the industry, bridging the gap between complex biological research and actionable clinical insights.
How much funding has RareCyte raised?
RareCyte has raised a total of $97M across 5 funding rounds:
Private Equity
$30M
Unspecified
$22M
Debt
$1M
Unspecified
$24M
Other Financing Round
$20M
Private Equity (2017): $30M with participation from Telegraph Hill Partners and 5AM Ventures
Unspecified (2019): $22M led by 5AM Ventures, HealthQuest Capital, and Ron Seubert
Debt (2020): $1M supported by PPP
Unspecified (2021): $24M featuring Agilent Technologies, F-Prime Capital Partners, 5AM Ventures, Logos Capital, HealthQuest Capital, and Arboretum Ventures
Other Financing Round (2024): $20M backed by HealthQuest Capital, F-Prime Capital Partners, 5AM Ventures, Arboretum Ventures, Agilent Technologies, and The Forest Road
Key Investors in RareCyte
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
Agilent Technologies
Agilent Technologies is a global leader in life sciences, diagnostics, and applied markets, providing laboratories worldwide with advanced instruments, software, consumables, and services.
F-Prime Capital Partners
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies.
What's next for RareCyte?
With the successful closure of this latest financing round, RareCyte is well-positioned to accelerate its commercial expansion and R&D initiatives. The strategic nature of this capital suggests a focus on scaling the adoption of its core platforms across global clinical and research markets. Moving forward, the company is likely to prioritize the integration of its diagnostic tools into broader healthcare ecosystems, potentially enhancing its competitive edge through strategic partnerships and technological refinements. By leveraging its established investor base, RareCyte is poised to navigate the complexities of the life sciences market, aiming to drive significant improvements in patient outcomes through its unique, high-resolution cellular analysis solutions.
See full RareCyte company page
